


PATENT
Docket No. 219002029210

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on May 13, 2004.


Rebecca McElroy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Sundee DUGAR et al.

Serial No.: 10/757,023

Filing Date: January 13, 2004

For: PIPERIDINE/PIPERAZINE-TYPE
INHIBITORS OF p38 KINASE

Examiner: Not Yet Assigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/990,184 filed 20 November 2001 and issued 24 February 2004 as U.S. Patent 6,696,443; accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 219002029210. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 13, 2004

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige.
Reg. No. 29,959
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 219002029210

Application Number 10/757,023

INFORMATION DISCLOSURE CITATION
BY AN APPLICATION

(Use several sheets if necessary)


Applicant

Sundeep DUGAR et al.

Filing Date January 13, 2004

Group Art Unit 1614

Mailing Date May 13, 2004



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10-10-2000	6,130,235	Mavunkel et al.	514	322	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	11/1992	EP 0 512 352	EP			
	3.	12/1996	WO 96/40143	PCT			
	4.	07/1997	WO 97/26252	PCT			
	5.	02/1998	WO 98/07425	PCT			
	6.	02/1998	WO 98/06715	PCT			
	7.	06/1999	WO 99/31096	PCT			
	8.	12/1999	WO 99/61426	PCT			
	9.	03/2000	WO 00/12074	PCT			
	10.	10/2000	WO 00/59904	PCT			
	11.	11/2000	WO 00/71535	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	12.	Scott et al. (1995). <i>Journal of Medicinal Chemistry</i> 38(21):4198-4210.
	13.	Chalmers (1996). <i>TIPS</i> 17:166-172.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.